Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines

Immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC). Prospective trials have focused on ICI treatment in the first or second line. The aim of this analysis is to evaluate the benefit of ICI across different treatment lines.This is a single-center retrospective study that included mRCC patients who received ICIs in various treatment lines. Objective response rates (ORR),...